Drug Profile
Research programme: serine/threonine protein kinase inhibitors - Traws Pharma
Alternative Names: CDK4 inhibitors - Onconova; ON 108110; ON-150030Latest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator Onconova Therapeutics
- Developer Icahn School of Medicine at Mount Sinai; Traws Pharma
- Class Antineoplastics; Pyrimidines; Thiazines
- Mechanism of Action Casein kinase II inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors; Fms-like tyrosine kinase 3 inhibitors; NUAK1 protein inhibitors; PIM3 protein inhibitors; Protein tyrosine kinase inhibitors; Protein-serine-threonine kinase inhibitors; Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Breast cancer; Cancer
Most Recent Events
- 02 Apr 2024 Trawsfynydd Therapeutics has merged with Onconova Therapeutics to form Traws Pharma
- 28 May 2021 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA
- 28 May 2019 No recent reports of development identified for research development in Breast-cancer in USA